Hims & Hers (HIMS) Ceases compounded semaglutide access following FDA action

Hims & Hers (HIMS) announced it will cease offering compounded semaglutide pills following the U.S. Food and Drug Administration's (FDA) decision to take action against the telehealth provider. The compounded weight-loss medication, sold for $49, is no longer available through the service. The FDA's enforcement actions are part of broader scrutiny of compounded drug sales and pricing practices.